Paul K. Audhya serves as the Chief Medical Officer at KalVista Pharmaceuticals Inc., a position he has held since joining the company. In his role, Dr. Audhya is responsible for overseeing the clinical development and medical strategy of KalVista's portfolio, which focuses on small molecule protease inhibitors targeting diseases with significant unmet need. His leadership has been instrumental in advancing the company's pipeline, particularly in the development of treatments for hereditary angioedema (HAE) and other complement-mediated disorders. Dr. Audhya brings a wealth of experience to KalVista, with a career spanning over two decades in the pharmaceutical industry. He has a strong background in clinical development, having held senior positions at several prominent biopharmaceutical companies. Prior to joining KalVista, he served as the Chief Medical Officer at Ra Pharmaceuticals, where he played a key role in the development and eventual acquisition of the company by UCB. His expertise in designing and executing clinical trials, as well as his deep understanding of regulatory processes, has been vital in driving KalVista's programs forward. Throughout his career, Dr. Audhya has been recognized for his contributions to the field of medicine and drug development. He holds an M.D. from the University of Toronto and completed his residency in internal medicine at the University of California, San Francisco. His commitment to improving patient outcomes and his strategic vision have made him a respected leader in the industry. At KalVista, Dr. Audhya continues to lead the charge in developing innovative therapies that have the potential to transform the lives of patients suffering from rare and life-threatening diseases.